Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trial In Progress
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors